Ibogaine in the Treatment of Substance Dependence
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Ibogaine is a psychoactive alkaloid derived from Tabernanthe iboga, a plant used in initiatory rituals in West Central Africa. Largely because of ibogaine's status as a Schedule I substance in the U.S., the development of ibogaine's use in the treatment of drug addiction took place outside conventional clinical and medical settings. This article reviews the history of ibogaine's use in the treatment of drug addiction, and discusses progress made towards, and obstacles blocking, the establishment of controlled clinical trials of ibogaine's efficacy. Preclinical research has generally supported anecdotal claims that ibogaine attenuates withdrawal symptoms and reduces drug cravings. Concerns about ibogaine's safety, as well as a dearth of solid data from human studies, have hampered progress in its development as an approved medication. This article outlines major findings from preclinical studies, discusses concerns about ibogaine's safety, and details previous and ongoing research on ibogaine's use as an anti-addictive treatment for humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“Secondary objectives include the post-treatment assessment of the intensity of withdrawal symptoms by means of the Subjective Opioid Withdrawal Scale (SOWS) [108]; the determination of the effectiveness of ibogaine to alleviate symptoms of depression for extended periods, as measured by the Beck Depression Inventory—I…”
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“some evidence to support such claims - for example, regarding LSD for opiate addiction [94] and for alcohol abuse [95].”
BackgroundThe Addiction Severity Index at 25: Origins, contributions, and transitions
McLellan, A. T., Cacciola, J. C., Alterman, A. I., Rikoon, S. H., & Carise, C. (2006) · The American Journal on Addictions · doi:10.1080/10550490500528316 · Cited by 450 · cited 4×
“Bastiaan’s study also broke new ground in considering the importance of assessing the efficacy of ibogaine treatment not only in terms of substance use, but also in terms other measures of overall quality of life that are often related to substance use and that are incorporated within such instruments as the Addiction…”
MethodInfluentialMcKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Maisonneuve, I. M., Keller, R. W., & Glick, S. D. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90634-3 · Cited by 126 · cited 1×
“A summary of findings across studies [7] reported that in studies using the naloxone-precipitated model of opiate detoxification, iboga alkaloids (specifically ibogaine, noribogaine, and 18-MC) have attenuated withdrawal signs in 13 of 14 independent investigations involving two rodent and two primate species [20, 22,…”
Background(2001) · The Alkaloids: Chemistry and Biology · doi:10.1016/s0099-9598(01)56006-x · Cited by 64
Cited by
Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives
Kumari, A., & Singh, R. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103021 · Cited by 583
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“1016/S0893-133X(00)00126-3 Lotsof, H. S. (1985). U.S. patent No. 4,499,096. Washington, DC: U.S. Patent and Trademark Office. Lotsof, H. S. (1995). Ibogaine in the treatment of chemical dependence disorders: Clinical perspectives.”
BackgroundMethodInfluentialWinkelman, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120011 · Cited by 126
“But the fatalities associated with ibogaine use in addiction treatment centers appear to be due to pre-existing medical conditions, specifically poor cardiac health, or as a consequence of using opioids or cocaine shortly before or after the ibogaine dose [44].”
BackgroundInfluentialArgento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. (2019) · Drug and Alcohol Review · doi:10.1111/dar.12985 · Cited by 102
Metadata
- Authors
- Brown, T.
- Venue
- Current Drug Abuse Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-06-01
- Volume
- 6
- Issue
- 1
- Pages
- 3-16
- ISSN
- 1874-4737 (ISSN-L)
- OpenAlex
- W2026484120
- Cited by
- 103
- References
- 7
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibogaine in the Treatment of Substance Dependence. https://app.cochat.ai/papers/10.2174/15672050113109990001
- The paper
- Brown, T. (2013). Ibogaine in the Treatment of Substance Dependence. Current Drug Abuse Reviews. https://doi.org/10.2174/15672050113109990001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.